Natural killer cell

Phase 2Biologic

SSt. Jude Children's Research Hospital

Natural killer cell is one of 54 biologic programs targeting Neuroblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaActive, not recruiting

NeuroblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

88 competitors in Neuroblastoma

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

52 2

Vepesid

AAvyxa

Phase 3

40 3

Paraplatin

AAvyxa

Phase 3

35 4

Leukine

Sanofi

Phase 3

15 5

Camptosar

Pfizer

Phase 3

12 6

Tepadina

Jazz Pharmaceuticals

Phase 3

11 7

Alkeran

AApotex Inc.

Phase 3

28 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

26 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroblastoma3 trials

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00698009·1 enrolled

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Quadruple Immunotherapy for Neuroblastoma

Recruiting·HHong Kong Children's Hospital·Phase 2·NCT05754684·29 enrolled

Leukemia1 trial

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01287104·34 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Biliary Tract Cancer1 trial

Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer

Completed·YYonsei University·Phase 1·NCT03358849·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Natural killer cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Natural killer cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Natural killer cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

Natural killer cell

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroblastoma3 trials

Leukemia1 trial

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News